RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
@DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translation .If clinical trials pan out to be successful ,it will be really “S.O.S “ (Save our Soul) for pancreatic cancers https://t.co/ASvcP
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @CD_AACR: Read the article here: https://t.co/7DEBRlcamy
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @CD_AACR: Read the article here: https://t.co/7DEBRlcamy
RT @CD_AACR: Read the article here: https://t.co/7DEBRlcamy
Read the article here: https://t.co/7DEBRlcamy
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @jpaArmand: Promishing+++ . Combined SOS1 and MEK inhibition represents a novel and effective therapeutic concept to address KRAS-driven…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @SyedAAhmad5: That’s a great description. @UCResearch @UCHealthNews @krushnacpatra @DavendraSohal
That’s a great description. @UCResearch @UCHealthNews @krushnacpatra @DavendraSohal
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
Promishing+++ . Combined SOS1 and MEK inhibition represents a novel and effective therapeutic concept to address KRAS-driven tumors.
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
K-Ras- the beating heart of cancer
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
Good work! KRAS-driven tumors are largely refractory to anticancer therapies. $FMTX MOA: https://t.co/WiTaEmEhXe
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @CD_AACR: ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined…
RT @JDHL18: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhi…
RT @CD_AACR: ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @CD_AACR: ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined…
RT @mlazqui: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inh…
RT @CD_AACR: ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 inhibitor BI-3406, just published in Cancer Research, slows KRAS beating, blocks feedback and kills KRAS mutant cancer cells. https://t.c
ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @norbertkraut1 @Boehringer #DrugDevelopment https://t.co/oSAiKGFB7v https://t.co/nPmttMLA5n
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition https://t.co/IY5r14c7h3
RT @mlazqui: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inh…
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition https://t.co/oNDcF9hpPh
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition | Cancer Discovery https://t.co/pHFRR3hfzq
BI-3406是一种有效且选择性的SOS1 :: KRAS相互作用抑制剂,通过联合MEK抑制可有效治疗KRAS驱动的癌症 https://t.co/VruRTmofTj
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @CD_AACR: Just published #OnlineFirst! BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven ca…
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
RT @boehringerus: #RESEARCHERS: In @CD_AACR, our scientists and partners show how our concept to combine a novel SOS1 inhibitor with a #MEK…
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @BenWestphalen: Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas d…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
RT @StephenVLiu: #OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 int…
#OncoAlert Report @CD_AACR by @norbertkraut1 @MarcoHHofmann describing BI-3406, small molecule that targets KRAS:SOS1 interaction. Several strategies targeting #KRAS out there - direct G12C, SHP2 - this particular drug should deplete GTP loading. https:
Interesting paper in @CD_AACR Data on a selective & orally bioavailable small-molecule SOS1 inhibitor targeting KRas driven cancers. The compound limited proliferation in KRas-driven #cancers & synergised with MEK inhibition. @KenOliveLab @OncoA
RT @Boehringer: #RESEARCHERS: In @CD_AACR, our scientists and partners show how our concept to combine a novel SOS1 inhibitor with a #MEKin…
#RESEARCHERS: In @CD_AACR, our scientists and partners show how our concept to combine a novel SOS1 inhibitor with a #MEKinhibitor works across a broad range of #KRAS mutations. To date, there are no effective pan-KRAS therapies.
RT @Boehringer: #RESEARCHERS: In @CD_AACR, our scientists and partners show how our concept to combine a novel SOS1 inhibitor with a #MEKin…
RT @gerlach_d: Targeting KRAS-driven cancers beyond G12C with combined SOS1::KRAS and MEK inhibition - breaking the feedback loop. Great wo…
RT @ElizSMcKenna: Now online in @CD_AACR: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven can…
RT @gerlach_d: Targeting KRAS-driven cancers beyond G12C with combined SOS1::KRAS and MEK inhibition - breaking the feedback loop. Great wo…
RT @RASopathiesnet: @Real_Dr_Kessler @D_B_McConnell Will be watching closely for application to #RASopathies Could BI-3406 be useful for…
RT @RASopathiesnet: @Real_Dr_Kessler @D_B_McConnell Will be watching closely for application to #RASopathies Could BI-3406 be useful for…
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition | Cancer Discovery https://t.co/OWKPUisEtf
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @Boehringer: #RESEARCHERS: In @CD_AACR, our scientists and partners show how our concept to combine a novel SOS1 inhibitor with a #MEKin…
RT @Boehringer: #RESEARCHERS: In @CD_AACR, our scientists and partners show how our concept to combine a novel SOS1 inhibitor with a #MEKin…
#RESEARCHERS: In @CD_AACR, our scientists and partners show how our concept to combine a novel SOS1 inhibitor with a #MEKinhibitor works across a broad range of #KRAS mutations. To date, there are no effective pan-KRAS therapies
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @gerlach_d: Targeting KRAS-driven cancers beyond G12C with combined SOS1::KRAS and MEK inhibition - breaking the feedback loop. Great wo…
RT @ElizSMcKenna: Now online in @CD_AACR: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven can…
RT @CD_AACR: Just published #OnlineFirst! BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven ca…
RT @norbertkraut1: Check out our paper in @CD_AACR where we present a compelling concept to aim at a broad range of #KRAS mutant cancers ht…
@neerajaiims @VivekSubbiah @timheff5 @MarcoHHofmann @norbertkraut1 @Real_Dr_Kessler @Aiims1742 @CancerMedMDA Here’s the link, should be open access. https://t.co/qa3qDg6HHq
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…